Gaskiya Diagnostics
-
DATABASE (8)
-
ARTICLES (11)
Founded in Nairobi in 2017, Chandaria Capital invests in African tech and non-tech startups across market segments. It currently has 13 companies in its portfolio. Recent investments include Kenyan diagnostics medtech startup Ilhara Health’s $3.8m Series A round in 2020 and $735,000 seed funding in 2019. The VC has also joined the seed investment round for Kenyan food and beverage startup Savannah Brand in 2019.
Founded in Nairobi in 2017, Chandaria Capital invests in African tech and non-tech startups across market segments. It currently has 13 companies in its portfolio. Recent investments include Kenyan diagnostics medtech startup Ilhara Health’s $3.8m Series A round in 2020 and $735,000 seed funding in 2019. The VC has also joined the seed investment round for Kenyan food and beverage startup Savannah Brand in 2019.
Founder and CEO of PesanLab
Dimas Prasetyo is the founder and CEO of PesanLab. He graduated with a degree in Medical Technology and Laboratory Science from Yogyakarta Health Polytechnic. He has over eight years of work experience in marketing, operations and management in the clinical laboratory diagnostics industry. He was also a product specialist at Non-invasive Genetic Abnormalities Test in Your Clinic and at Natera Inc. He co-founded Lab Panorama Bandung in 2009 and left in 2013 to become the founder of LabConX that was later rebranded as PesanLab.
Dimas Prasetyo is the founder and CEO of PesanLab. He graduated with a degree in Medical Technology and Laboratory Science from Yogyakarta Health Polytechnic. He has over eight years of work experience in marketing, operations and management in the clinical laboratory diagnostics industry. He was also a product specialist at Non-invasive Genetic Abnormalities Test in Your Clinic and at Natera Inc. He co-founded Lab Panorama Bandung in 2009 and left in 2013 to become the founder of LabConX that was later rebranded as PesanLab.
Co-founder of Therapixal
Olivier Clatz is the French co-founder of AI medical diagnosis company Therapixel, creator of MammoScreen breast cancer screening and diagnosis tool. Prior to co-founding Therapixel, Clatz worked for six years as a research scientist at INRIA (National Institute for Research in Digital Science and Technology) based at the Sophia Antipolis technology park near Antibes, in the south of France. His later work with INRIA focused on exploiting machine learning algorithms for medical imaging processing. Prior to this, he was a research associate at Harvard Medical School, in the US. In 2006, he completed his PhD at INRIA on the concept of personalized medicine. Clatz also holds a PhD in philosophy from the Ecole des Mines de Paris, and a master's degree in applied mathematics from the Ecole Normale Supérieure Paris-Saclay. Currently, he works at the French Government’s Commissariat Générale pour l’Investissement managing the national program AI For Diagnostics. He left Therapixel in 2019.
Olivier Clatz is the French co-founder of AI medical diagnosis company Therapixel, creator of MammoScreen breast cancer screening and diagnosis tool. Prior to co-founding Therapixel, Clatz worked for six years as a research scientist at INRIA (National Institute for Research in Digital Science and Technology) based at the Sophia Antipolis technology park near Antibes, in the south of France. His later work with INRIA focused on exploiting machine learning algorithms for medical imaging processing. Prior to this, he was a research associate at Harvard Medical School, in the US. In 2006, he completed his PhD at INRIA on the concept of personalized medicine. Clatz also holds a PhD in philosophy from the Ecole des Mines de Paris, and a master's degree in applied mathematics from the Ecole Normale Supérieure Paris-Saclay. Currently, he works at the French Government’s Commissariat Générale pour l’Investissement managing the national program AI For Diagnostics. He left Therapixel in 2019.
Young data scientist Gabriel Leupin is proficient in Python and SQL. He has a degree in French language and literature, with a minor in Philosophy from the Louisiana State University. He has also completed business programs at Université Denis Diderot (Paris VII) and studied statistics, data mining and analysis at Stanford University.He has worked as a research assistant in CORE Diagnostics and as a business developer in PogoLab. He has also taught languages at the Académie de Creteil and has invested in various businesses.
Young data scientist Gabriel Leupin is proficient in Python and SQL. He has a degree in French language and literature, with a minor in Philosophy from the Louisiana State University. He has also completed business programs at Université Denis Diderot (Paris VII) and studied statistics, data mining and analysis at Stanford University.He has worked as a research assistant in CORE Diagnostics and as a business developer in PogoLab. He has also taught languages at the Académie de Creteil and has invested in various businesses.
Alta Life Sciences (Alta LS) was established in 2016. Based in Barcelona, the management team is led by the co-founder of Alta Partners Guy Paul Nohra, a leading pioneer VC in life sciences. Alta Partners has funded over 150 companies since 1996. Alta LS specializes in the life sciences sector in Spain and abroad, targeting biotech, genomics, medical devices, diagnostics and digital health. It also acts as a bridge fund, connecting the Spanish life sciences ecosystem to VC experts in Silicon Valley. Investment is available for all stages of development, with focus mainly on seed and Series A funding.
Alta Life Sciences (Alta LS) was established in 2016. Based in Barcelona, the management team is led by the co-founder of Alta Partners Guy Paul Nohra, a leading pioneer VC in life sciences. Alta Partners has funded over 150 companies since 1996. Alta LS specializes in the life sciences sector in Spain and abroad, targeting biotech, genomics, medical devices, diagnostics and digital health. It also acts as a bridge fund, connecting the Spanish life sciences ecosystem to VC experts in Silicon Valley. Investment is available for all stages of development, with focus mainly on seed and Series A funding.
Verizon Ventures is the venture capital arm of Verizon Communications, the US's largest wireless provider, established in 2000. It invests from Series A to IPO. Verizon Ventures has made more than 100 investments to date and managed 20 exits, including healthcare diagnostics company NantHealth and P2P video content service Streamroot. Recent investments include holographic lighting technology company Light Field Lab's US$28m Series A round and AI-powered mass transportation technology company Optibus's US$40m Series B round.
Verizon Ventures is the venture capital arm of Verizon Communications, the US's largest wireless provider, established in 2000. It invests from Series A to IPO. Verizon Ventures has made more than 100 investments to date and managed 20 exits, including healthcare diagnostics company NantHealth and P2P video content service Streamroot. Recent investments include holographic lighting technology company Light Field Lab's US$28m Series A round and AI-powered mass transportation technology company Optibus's US$40m Series B round.
Mayfield Fund is one of Silicon Valley's oldest venture capital firms. Founded by Wally Davis and Thomas J Davis Jr in 1969, the VC is based in Menlo Park, California.Current investments include CRISPR-focused companies like Mammoth Biosciences and biotech startup iLoF,l which is focused on creating a digital library of optical fingerprints for non-invasive patient screening, early diagnostics and personalized medical treatments.. With a total of $2.5bn assets under management, the firm focuses mainly on early-stage to growth-stage investments. The VC has also backed startups like Marketo, Lyft and SolarCity. Most of Mayfield’s exits took place during the 2008 financial crisis and through subsequent funds.In April 2020, amid the Covid-19 pandemic, Mayfield announced two new funds which raised $750m in total. Mayfield XVI will invest in early-stage companies, while Mayfield Select II will focus on growth-stage companies outside its portfolio. The company said last year that it has raised a similar size fund every four years and has invested in 30 companies per fund. It primarily leads Series A investments.
Mayfield Fund is one of Silicon Valley's oldest venture capital firms. Founded by Wally Davis and Thomas J Davis Jr in 1969, the VC is based in Menlo Park, California.Current investments include CRISPR-focused companies like Mammoth Biosciences and biotech startup iLoF,l which is focused on creating a digital library of optical fingerprints for non-invasive patient screening, early diagnostics and personalized medical treatments.. With a total of $2.5bn assets under management, the firm focuses mainly on early-stage to growth-stage investments. The VC has also backed startups like Marketo, Lyft and SolarCity. Most of Mayfield’s exits took place during the 2008 financial crisis and through subsequent funds.In April 2020, amid the Covid-19 pandemic, Mayfield announced two new funds which raised $750m in total. Mayfield XVI will invest in early-stage companies, while Mayfield Select II will focus on growth-stage companies outside its portfolio. The company said last year that it has raised a similar size fund every four years and has invested in 30 companies per fund. It primarily leads Series A investments.
LeapFrog Investments is an impact-focused investor, managing over $1.6bn in assets mainly investing in Africa and Asia. Its “profit with purpose” has led to investments in startups that provide healthcare, financial services and insurance for low-income consumers. Since it was founded in 2007, LeapFrog has attracted funds from Prudential, AXA, Swiss Re and Omidyar Network, becoming the first impact investor in the world to reach the $1bn milestone. It’s headquartered in South Africa and Singapore.LeapFrog is best known for its investments in the insurance sector. One of the most prominent companies in its portfolio is BIMA, the mobile-based insurance provider that has provided coverage in Ghana, Bangladesh, Cambodia and many other countries. In 2020, LeapFrog invested in Indonesian startup PasarPolis, which is a broker for a wide range of microinsurance products. In the healthcare and biotechnology sectors, LeapFrog has funded Indian genetic diagnostics company MedGenome, as well as Goodlife Pharmacy, a Kenyan company providing access to affordable medicine in the East African country.
LeapFrog Investments is an impact-focused investor, managing over $1.6bn in assets mainly investing in Africa and Asia. Its “profit with purpose” has led to investments in startups that provide healthcare, financial services and insurance for low-income consumers. Since it was founded in 2007, LeapFrog has attracted funds from Prudential, AXA, Swiss Re and Omidyar Network, becoming the first impact investor in the world to reach the $1bn milestone. It’s headquartered in South Africa and Singapore.LeapFrog is best known for its investments in the insurance sector. One of the most prominent companies in its portfolio is BIMA, the mobile-based insurance provider that has provided coverage in Ghana, Bangladesh, Cambodia and many other countries. In 2020, LeapFrog invested in Indonesian startup PasarPolis, which is a broker for a wide range of microinsurance products. In the healthcare and biotechnology sectors, LeapFrog has funded Indian genetic diagnostics company MedGenome, as well as Goodlife Pharmacy, a Kenyan company providing access to affordable medicine in the East African country.
Early Charm Ventures: Taking research from the labs to the real world
Instead of investing money, the venture studio gets hands-on, co-running companies with top scientists and their cutting-edge research
BioMind: AI medical diagnostics with over 90% accuracy for 100 diseases
BioMind helps doctors save lives by providing more accurate diagnosis of life-threatening diseases like Covid-19 and brain tumors
iLoF: Accelerating access to personalized medicine, from a drop of blood
Backed by Microsoft’s venture fund M12, Mayfield and Melinda Gates’s Pivotal Ventures, iLoF focuses on painless screening to facilitate disease detection, forecasting and drug development, from Alzheimer’s to Covid-19
Daniel Oliver: Building a "Facebook" for investments in biotech startups
The biologist and crowdfunding expert has pioneered the growth of Spanish biotech startups, providing access to early-stage investments, with support from scientific experts worldwide
BeeHero: Agritech for bee health and better crop pollination
Combining AI, smart sensors and the world’s largest bee database, BeeHero accurately predicts disorders in colonies, helping beekeepers reduce the mortality rate of bees vital for crop pollination
SWITCH Singapore 2021: Benefits and challenges of AI applications in healthcare
Medical experts and healthcare startups agree AI can contribute more to healthcare beyond improving diagnosis and personalized treatment, but hurdles still remain
B’Smart: Innovative IoT systems add ML for smart fleet management
Pivoting from Wi-Fi systems to smart fleet management, B'Smart is expanding rapidly to tap the US$12.7bn IoT for logistics market
Bewe: From LatAm to the US, scaling fitness and wellness business globally post-Covid
Serial entrepreneur Diego Ballesteros’s latest venture Bewe seeks to disrupt the lucrative US wellness and fitness market with more competitive pricing
Aimentia: Pioneering mental health AI SaaS seeks to improve diagnosis as demand surges
Barcelona-based Aimentia supports the oft-overlooked mental health segment through digitalization and analytics, going beyond therapy platforms
With a new focus on smart clinics, healthcare SaaS startup Medigo offers Covid-19 testing
A pivot to revenue-sharing and partnerships to provide Covid-19 testing has given Medigo a fighting chance, with a new funding round on the cards
Animal AgTech Innovation Summit 2021: Experts discuss post-pandemic priorities
The pandemic not only put digital tech in everyone’s hands, it also forced thinking about collecting meaningful data and moving it on-demand to both producers and decision makers
Sorry, we couldn’t find any matches for“Gaskiya Diagnostics”.
POPULAR DATABASE
